Top 10 Medical Aesthetics Companies | By Experienced Medical Practitioners

Medical Aesthetics Market Overview

Medical aesthetics comprises non-surgical procedures experienced medical practitioners conduct to enhance a person’s appearance. These interventions encompass Botox for wrinkle reduction, dermal fillers for facial volume augmentation, and laser therapy to enhance skin texture.

The primary objective is to bolster individuals’ self-assurance by addressing cosmetic issues like fine lines, wrinkles, and skin blemishes. It is crucial to underscore that certified professionals should administer these treatments to guarantee their safety and efficacy.

Market Drivers

Increased Awareness about Using Medical Aesthetics

There’s a rising demand for cosmetic procedures that don’t require surgery, particularly among those wanting to enhance their appearance. Many individuals prefer these less invasive options to tackle issues like aging skin, resulting in a notable increase in the popularity of treatments such as Botox and dermal fillers.

Moreover, advancements in technology and ongoing product innovation are driving market expansion. The ongoing research and development in medical aesthetics have led to safer and more efficient treatments, making this industry increasingly appealing to patients and healthcare professionals.

Market Size

The Global Medical Aesthetics Market is projected to grow significantly, going from USD 15.3 Billion in 2022 to an estimated USD 51.7 Billion by 2032. This growth is expected to occur steadily at a 13.3% CAGR from 2023 to 2032.

Medical Aesthetics Market: Top Key Players

• Cynosure
• Galderma
• Lumenis
• Merz-Pharmaceuticals
• Syneron-Medical
• Mentor-Worldwide
• Cutera
• Solta-Medical
• Bausch-Health
• El-En-SpA

Cynosure

Company Overview

Establishment Year	1991
Headquarter	The U.S.
Key Management	Nadav Tomer (CEO)
Revenue (US$ Mn)	$332.1M (2022)
Headcount	~1,253 (2022)
Website	www.cynosure.com

About Cynosure

Cynosure has earned a respected position in medical aesthetics, specializing in advanced laser and light-based technologies designed to address various aspects of beauty and well-being. Their product range includes solutions for tasks like hair removal, skin rejuvenation, body contouring, tattoo removal, and the treatment of vascular and pigmented lesions, as well as cellulite.

Cynosure is known for its unwavering commitment to research and development, ensuring that healthcare professionals can use their products confidently and safely. They also offer support through training and have a global presence with a network of distributors and service centers. Their technology serves a dual purpose by enhancing physical appearance and addressing skin-related concerns associated with aging.

Geographical Presence

Cynosure has established a notable presence in several countries, including the United States, Australia, the United Kingdom, France, Spain, Portugal, Germany, Morocco, Japan, and Korea, ensuring their advanced aesthetic and medical technologies are available to a broad international audience.

Recent Developments

• May 2022: CD&R invested $60 million in Cynosure to boost its growth and innovation efforts, focusing on enhancing customer service and solutions.
• April 2021: Cynosure disclosed its acquisition agreement for the MyEllevate Surgical Suture System, broadening its product offerings.

Galderma

Company Overview

Establishment Year	1981
Headquarter	Switzerland.
Key Management	Flemming Ørnskov (CEO)
Revenue (US$ Bn)	$ 3.417 Billion (2022)
Headcount	~ 5,700  (2022)
Website	www.galderma.com

About Galderma

Founded in 1981 by dermatologists, Galderma is a prominent player in dermatology and aesthetics. This global pharmaceutical company is exclusively dedicated to dermatology and skin health. With a strong emphasis on research, development, and innovation, Galderma aims to provide top-quality skincare solutions that enhance people’s lives worldwide.

Their wide-ranging product portfolio includes prescription medications and over-the-counter treatments, addressing various dermatological conditions like acne, rosacea, psoriasis, and aging skin. Galderma’s commitment to dermatology is evident through its collaborations with healthcare professionals, patients, and skin health organizations. By continually advancing the frontiers of dermatological science, Galderma strives to boost the well-being and self-assurance of individuals by delivering effective and safe skincare solutions.

Geographical Presence

Galderma’s global presence spans 50 sites across 40 countries, with its headquarters in Switzerland. Additionally, they have sponsored clinical trials in over 30 countries since 2020, reflecting their commitment to advancing dermatological solutions worldwide.

Recent Developments

• June 2023: Galderma secured around $1 billion by issuing new shares during a private placement round. The funds raised will bolster the company’s financial position and contribute to the continued expansion of its organic growth initiatives, driven by its distinctive integrated dermatology strategy.
• January 2022: Galderma acquired ALASTIN Skincare, known for innovative physician-dispensed skincare. This partnership enhances Galderma’s ability to meet the needs of aesthetic professionals and patients by combining their expertise.

Lumenis

Company Overview

Establishment Year	1991
Headquarter	Israel
Key Management	Tzipi Ozer-Armon (CEO)
Revenue (US$ Bn)	$425.0 Million (2022)
Headcount	~ 1,500 (2022)
Website	https://lumenis.com/

About Lumenis

Lumenis, founded in 1966 by physicist and engineer Mr. Yacha Sutton, is a leading global provider of innovative energy-based medical solutions. With decades of experience, the company specializes in developing cutting-edge laser and light-based technologies that address various medical and aesthetic applications.

Lumenis is dedicated to improving the quality of life for patients worldwide by offering safe, effective, and minimally invasive solutions for various medical conditions and cosmetic procedures. Throughout its history, Lumenis has remained at the forefront of technological advancements in the healthcare industry, significantly impacting patient care and medical outcomes.

Geographical Presence

Lumenis operates in numerous countries, including the United States, Canada, Mexico, Brazil, the United Kingdom, France, Germany, Italy, Spain, Israel, India, China, Japan, Australia, and many more.

Recent Developments

• March 2021: Lumenis completed the sale of its surgical division to Boston Scientific for an initial cash payment of $1.07 billion. This strategic move enabled Lumenis to concentrate entirely on its Aesthetics and Vision divisions, setting the stage for pursuing fresh avenues of growth in the upcoming year.
• February 2021: Lumenis’ surgical division was sold to Boston Scientific for $1.07 billion. This transaction bolstered Lumenis’ capacity to channel more resources into its Aesthetics and Vision segments, facilitating investments in research and development, expanding its global sales and marketing reach, and advancing its business development endeavors.

Merz-Pharmaceuticals

Company Overview

Establishment Year	1908
Headquarter	Germany
Key Management	Philip Burchard (CEO)
Revenue (US$ Bn)	$1.441 billion (2022)
Headcount	~ 3,730  (2022)
Website	www.merz.com

About Merz Pharmaceuticals

Founded by Friedrich Merz in 1908, Merz Pharmaceuticals is a highly respected healthcare company celebrated for its century-long leadership in medical progress. The company excels in crafting, manufacturing, and delivering pharmaceutical and medical aesthetic products.

Merz Pharmaceuticals has achieved worldwide acclaim for its unwavering dedication to improving healthcare solutions and enriching patients’ lives globally. With a rich history and an unwavering commitment to research and development, the company maintains a prominent position in the global healthcare industry, offering innovative treatments and therapies across various medical fields.

Geographical Presence

Merz Pharmaceuticals, a global healthcare company headquartered in Frankfurt, Germany, has established a significant geographical presence across multiple countries worldwide. They have a strong presence in Europe, particularly Germany, France, the United Kingdom, and Italy. In North America, Merz has a substantial presence with offices and operations in the United States and Canada.

Furthermore, they have expanded their reach to Asia, with a notable presence in Japan, South Korea, and China. In Latin America, they operate in countries such as Brazil and Mexico. Merz also has a growing footprint in the Middle East and Africa, in countries like the United Arab Emirates and South Africa.

Recent Developments

• February 2022: Vensica Therapeutics, a biopharmaceutical company in the clinical stage, successfully concluded a $19 million investment round, establishing a strategic partnership with Merz.

Syneron-Medical

Company Overview

Establishment Year	2000
Headquarter	The U.S.
Key Management	Geoffrey S. Crouse (CEO)
Revenue (US$ Mn)	$321.7Million  (2022)
Headcount	~ 860(2022)
Website	https://candelamedical.com/

About Syneron Medical

Established by Shimon Eckhouse in 2000, Syneron Medical Ltd is a worldwide medical technology enterprise. It has been a trailblazer in non-invasive medical and aesthetic treatments, focusing on creating and delivering groundbreaking devices for various dermatological and cosmetic uses.

Through its state-of-the-art technologies, Syneron Medical has earned a prominent position within the industry, offering sophisticated solutions to healthcare experts and individuals worldwide, elevating the standards of both aesthetic and medical care.

Geographical Presence

Syneron Medical Ltd. is prominently situated in North America, specifically the United States, serving the diverse requirements of the healthcare and aesthetic sectors. They have also firmly established themselves in Europe, with offices and activities in countries like France, Germany, and the United Kingdom. Furthermore, they have expanded their influence into Asia, with a substantial presence in markets such as Japan and South Korea.

Recent Developments

• February 2023: Candela Corporation, also known as Candela, has gained FDA and Health Canada approvals to broaden the applications of the PicoWay laser system. This expansion includes treating melasma, along with its existing uses for various skin conditions like wrinkles, pigmented lesions, tattoo removal, acne scars, lentigines, café au lait macules (CALMs), and Nevus of Ota.

Mentor-Worldwide

Company Overview

Establishment Year	1969
Headquarter	The U.S.
Key Management	Edward S. Northup, (COO)
Revenue (US$ Mn)	$ 302 million (2007)
Headcount	~2000 (2007)
Website	www.mentorwwllc.com

About Mentor Worldwide

Mentor Worldwide LLC, established in 1969 by Dr. Thomas D. Cronin, is a prominent company specializing in medical aesthetics. Mentor Worldwide LLC is a well-known company specializing in medical aesthetics. Known for its extensive experience, unwavering dedication to excellence, and innovative approach, Mentor has established itself as a top supplier of breast implants and body contouring solutions.

Their steadfast commitment to patient safety and contentment has earned them the trust of healthcare practitioners and patients. Mentor Worldwide LLC remains at the forefront of the aesthetic industry, providing top-notch solutions that boost the confidence and overall well-being of individuals seeking aesthetic enhancements.

Geographical Presence

With its headquarters in the United States, the company has a strong presence in North America, particularly in the United States and Canada. In Europe, Mentor serves healthcare providers and patients in countries such as the United Kingdom, France, Germany, and Italy. Additionally, the company extends its reach to other regions, including Asia, with a presence in countries like Japan and South Korea.

Recent Developments

• August 2023: Mentor Worldwide LLC, a subsidiary of Johnson & Johnson Medical Devices Companies, introduced the Mentor New Practice Program. This initiative is crafted to assist plastic surgeons in launching and expanding their practices.
• January 2022: Mentor Worldwide LLC received FDA clearance to utilize their MENTOR MemoryGel BOOST Breast Implant in breast augmentation for women who are 22 years and older, as well as in breast reconstruction for women of all age groups.

Cutera

Company Overview

Establishment Year	1998
Headquarter	The U.S.
Key Management	David H. Mowry (CEO)
Revenue (US$ Mn)	$252.4 million (2022)
Headcount	~540 (2022)
Website	https://cutera.com/

About Cutera

Established in 1998, Cutera is a well-known player in medical aesthetics. Over the years, the company has gained a reputation for its cutting-edge aesthetic solutions. Cutera focuses on creating and supplying advanced aesthetic and laser devices, catering to various skin-related issues such as hair removal, rejuvenation, and body contouring.

Through its dedication to research and development, Cutera has successfully provided top-tier technology to healthcare professionals around the world, empowering them to boost the self-assurance and overall well-being of their patients.

Geographical Presence

The company, headquartered in the United States, has a strong presence in North America, particularly in the United States and Canada. In Europe, Cutera operates in countries like the United Kingdom, France, Germany, and Italy. Additionally, the company extends its reach to Asia, with a presence in countries such as Japan and South Korea.

Recent Developments

• September 2023: Cutera unveiled its latest skin resurfacing and revitalization platform, Secret DUO.
• May 2023: Cutera entered into agreements with two investment firms, Pura Vida and RTW, leading to the appointment of new directors to its Board.

Solta-Medical

Company Overview

Establishment Year	1996
Headquarter	California, U.S.
Key Management	Scott Hirsch (CEO)
Revenue (US$ Mn)	$68.4Million (2022)
Headcount	~352 (2022)
Website	www.solta.com

About Solta Medical

Founded in 1996 by Douglas J. Constant, Solta Medical International Inc. is a notable player in medical aesthetics. Specializing in innovative solutions for skin rejuvenation and body shaping, the company offers a range of cutting-edge devices and technologies to address cosmetic concerns such as wrinkles, acne scars, and excess fat.

With a strong commitment to research and advancement, Solta Medical International Inc. has earned a reputation for providing state-of-the-art technology to healthcare practitioners, helping enhance the self-assurance and overall health of their patients.

Geographical Presence

Headquartered in the United States, the company maintains a strong presence in North America, particularly in the United States and Canada. In Europe, Solta Medical International Inc. operates in countries like the United Kingdom, France, Germany, and Italy. Additionally, the company extends its reach to Asia, with a presence in countries such as Japan and South Korea.

Recent Developments

• June 2022: Solta Medical offers advanced solutions for skin rejuvenation and body contouring, including Thermage RF, Fraxel laser, Clear + Brilliant laser, and VASER ultrasonic systems.
• February 2022: Solta Medical, which falls under the ownership of Bausch Health, intended to initiate an initial public offering (IPO) for its company.

Bausch-Health

Company Overview

Establishment Year	1959
Headquarter	Canada
Key Management	Thomas Appio (CEO)
Revenue (US$ Bn)	$8.1 billion (2022)
Headcount	~ 19,600 (2021)
Website	www.bauschhealth.com

About Bausch Health

Bausch Health Companies Inc., originally founded in 1853 by J.J. Bausch and Henry Lomb, has a rich history in the healthcare industry. Formerly known as Valeant Pharmaceuticals International Inc., the company has evolved to become a leading global pharmaceutical and medical device firm.

Bausch Health is committed to improving the health and well-being of people worldwide by offering a wide range of pharmaceuticals, medical devices, and over-the-counter products. With a focus on innovation, research, and development, the company is vital in advancing medical solutions and treatments across various therapeutic areas, ensuring better health outcomes for patients worldwide.

Geographical Presence

Bausch Health Companies Inc. holds a substantial worldwide footprint, catering to patients and healthcare experts in numerous nations. Based in Canada, the company has a robust presence in North America, particularly in the United States, where it offers a broad array of pharmaceuticals and medical equipment. Bausch Health further expands its influence into Europe, with activities in nations like the United Kingdom, France, Germany, and Italy. Moreover, the company has established a notable foothold in Asia, with operations in Japan and South Korea.

Recent Developments

• May 2022: Bausch Health revealed its plans to invest $300 million in its Canadian manufacturing operations over the upcoming five years. This substantial investment bolsters the company’s expansion and advancement within the pharmaceutical sector, including creating novel products and technologies.

El-En-SpA

Company Overview

Establishment Year	1981
Headquarter	Italy
Key Management	Gabriele Clementi (CEO)
Revenue (US$ Bn)	$449 million (2020)
Headcount	~ 2500 (2020)
Website	https://elengroup.com/

About El.En. SpA

Established in 1981, El.En. SpA is a well-known Italian firm renowned for its laser and photonics technology expertise. It is prominent in this sector and focuses on creating, producing, and providing high-quality laser systems and solutions.

These products serve various purposes, including medical, industrial, and aesthetic applications. El.En. SpA is recognized for its steadfast commitment to research and advancement, leading to cutting-edge laser technologies that profoundly influence various sectors, such as healthcare and manufacturing.

Geographical Presence

El.En. SpA has established a noteworthy global presence, providing its laser and photonics technology solutions to clients and industries worldwide. Headquartered in Italy, the company has a strong presence in Europe, particularly in countries like Germany, France, and the United Kingdom. Additionally, El.En. Extends its reach to North America, with operations in the United States and Canada. The company also has a growing presence in Asia, serving markets such as China and Japan.

Recent Developments

• February 2023: Quanta System S.p.A., a division of El.En., donated a laser for critical pediatric medical use to the non-profit group Manzo-Prod-Action-Aid in Florence. This laser will be installed soon in Zimbabwe, in the Chinoyi diocese, to support Pediatric Outpatient Clinics at St. Albert’s, Marymount, Rupert’s, and Chitsungo Mission Hospitals.